Semaglutide is a long-acting GLP-1 receptor agonist developed as a synthetic analogue of the endogenous incretin hormone GLP-1. It is one of the most extensively studied GLP-1 receptor agonists in the research literature, with preclinical data supporting appetite suppression, slowed gastric emptying, and improved glycaemic regulation. It is studied for obesity, metabolic syndrome, and type 2 diabetes-related research applications.
Semaglutide
$90.00Price
- Potent GLP-1 receptor agonist — reduces appetite and slows gastric emptying in preclinical models
- Studied for significant fat mass reduction and body composition changes in metabolic research
- Supports glycaemic regulation through glucose-dependent insulin secretion and glucagon suppression
- Investigated for cardiovascular risk factor modulation in metabolic disease research models
- Long-acting acylation chemistry supports extended half-life for once-weekly research protocols
